|1.||Matsumura, Yasuo: 5 articles (12/2009 - 09/2002)|
|2.||Rae, Giles Alexander: 4 articles (06/2010 - 06/2006)|
|3.||Takaoka, Masanori: 4 articles (01/2005 - 09/2002)|
|4.||Chichorro, Juliana Geremias: 3 articles (06/2010 - 06/2006)|
|5.||Rae, Giles A: 2 articles (05/2009 - 04/2009)|
|6.||D'Orléans-Juste, Pedro: 2 articles (05/2009 - 06/2006)|
|7.||Chichorro, Juliana G: 2 articles (05/2009 - 04/2009)|
|8.||Zampronio, Aleksander Roberto: 2 articles (07/2006 - 06/2006)|
|9.||Matsumoto, Noriko: 2 articles (01/2005 - 11/2004)|
|10.||Gariepy, Cheryl E: 2 articles (01/2005 - 09/2002)|
|1.||Pulmonary Hypertension (Ayerza Syndrome)
01/01/1999 - "SB 247083, but not A-192621, inhibited hypoxia-induced pulmonary hypertension, whereas A-192621, but not SB 247083, significantly exacerbated hypoxia-induced increases in ET concentrations, suggesting that hypoxia-induced pulmonary pressor responses are mediated via ETA receptor activation, while ETB receptor blockade may alter clearance of hypoxia-induced elevated plasma ET. "
12/15/1999 - "Administration of A-192621 alone resulted in cardiovascular collapse and death whereas combining A-192621 with PD 155080 abolished endotoxin induced pulmonary hypertension, enhanced cardiac performance and improved systemic oxygen delivery and acid-base balance. "
08/01/2004 - "The functional roles of endothelin ETA and ETB receptors in the development of monocrotaline (MCT)-induced pulmonary hypertension were investigated using MCT-treated rats in the absence or presence of a daily administration of A-192621, a selective ETB receptor antagonist, ABT-627, a selective ETA receptor antagonist, or a combination of both drugs. "
11/01/2004 - "Similarly, chronic treatment with ABT-627 totally abolished the systemic and renal vasoconstriction caused by injected ET-1 in rats with congestive heart failure, whereas A192621 potentiated these effects. "
11/01/2004 - "Interestingly, treatment with either ABT-627 or A192621 significantly decreased cardiac hypertrophy in rats with congestive heart failure. "
11/01/2004 - "Chronic treatment of animals with congestive heart failure with ABT-627 did not influence daily sodium excretion, whereas treatment with A192621 significantly improved daily sodium excretion. "
11/01/2004 - "The present study examined the renal and systemic effects of chronically administered ABT-627 (24 mg/kg per day) or A-192621 (72 mg/kg per day) for 7 days via osmotic minipumps inserted intraperitoneally on the day of operation of sham controls and rats with congestive heart failure. "
08/01/2002 - "The present study examined the effects of two highly selective endothelin-1 (ET-1) receptor antagonists, ABT-627 (ET(A) blocker) and A-192621 (ET(B) blocker), on the systemic and renal haemodynamic effects of ET-1 in normal rats and in rats with experimental congestive heart failure (CHF) produced by aortocaval fistula. "
|3.||Melanoma (Melanoma, Malignant)
02/15/2004 - "The small molecule A-192621, an orally bioavailable nonpeptide ET(B)R antagonist, significantly inhibits melanoma growth in nude mice. "
01/01/2008 - "Instead, we present evidence that A-192621 affects glioma and melanoma viability by activating stress/DNA damage response pathways, which leads to cell cycle arrest and apoptosis. "
01/01/2008 - "Importantly, reducing expression of ETRB with siRNAs does not abrogate the effects of either A-192621 or BQ788 in glioma or melanoma cells. "
11/01/2004 - "A-192621, an orally active non-peptide endothelin-B receptor antagonist, significantly inhibited melanoma growth in nude mice, suggesting that the pharmacological interruption of endothelin-B receptor signaling by endothelin-B receptor antagonist may represent a new therapeutic approach in the treatment of cutaneous melanoma."
10/01/2012 - "That EDNRB contributes to melanoma metastasis is underscored by the fact that its therapeutic inhibition by the EDNRB-specific inhibitor A192621 translated into improved outcomes when treating mice with either visceral metastases or intracranial tumors. "
01/25/2005 - "In Sprague-Dawley rat hearts, ischemia/reperfusion-induced cardiac dysfunctions such as decreased left ventricular developed pressure and coronary flow and increased left ventricular end-diastolic pressure were worsened by treatment with A-192621. "
11/01/2004 - "An ETB receptor antagonist A-192621 at 1 microM worsened ischemia/reperfusion-induced cardiac dysfunction. "
04/01/2000 - "ABT-627 (1 mg/kg, i.v.) administration before ischemia markedly attenuated the renal dysfunction induced by the ischemia/reperfusion, whereas A-192621 (3 mg/kg, i.v.) pretreatment was without effect. "
04/01/2000 - "Daily oral administration of ABT-627 (10 mg/kg per day), but not A-192621 (30 mg/kg per day), given after the ischemia/reperfusion period also exerted protective effects. "
11/01/2004 - "Treatment with ABT-627 significantly suppressed the norepinephrine overflow induced by the ischemia/reperfusion whereas A-192621 further enhanced it, which was completely abolished by the concomitant treatment with ABT-627. "
|6.||Endothelin-1 (Endothelin 1)
|7.||salicylhydroxamic acid (SHAM)